HWKN HAWKINS INC
Wholesale-Chemicals & Allied Products · Nasdaq · SEC CIK 46250 · Fiscal year ends 03/28
Financial factors as of 2026-09-27 (2027Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.0%
TTM net income YoY3.2%
TTM EPS YoY3.8%
Revenue 3-yr CAGR6.8%
Net income 3-yr CAGR7.5%
Margins
Gross margin22.4%
Operating margin11.1%
Net margin7.5%
FCF margin8.1%
EBITDA margin16.0%
Returns
ROE16.0%
ROA8.6%
ROIC (approx.)12.8%
Asset turnover1.14x
Leverage & solvency
Liabilities / assets44.3%
Debt / equity0.41x
Current ratio2.28x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.73x
Accruals ratio-6.3%
Payout ratio18.7%
Capex / revenue4.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-29 | FY20252025-03-30 |
|---|---|---|
| Income statement | ||
| Revenue | $1.08B | $974.43M |
| Cost of revenue | $838.64M | $748.89M |
| Gross profit | $245.06M | $225.54M |
| SG&A expense | $123.76M | $106.36M |
| Operating income | $121.29M | $119.17M |
| Pretax income | $109.34M | $114.38M |
| Income tax | $27.79M | $30.04M |
| Net income | $81.55M | $84.34M |
| EBITDA | $173.84M | $159.12M |
| EPS (basic) | 3.93 | 4.05 |
| EPS (diluted) | 3.91 | 4.03 |
| Dividends declared per share | 0.75 | 0.70 |
| Weighted avg. shares (diluted) | 20.86M | 20.94M |
| Banking | ||
| Net interest income | -$13.51M | -$5.43M |
| Balance sheet | ||
| Cash & equivalents | $3.91M | $5.10M |
| Receivables | $139.80M | $131.79M |
| Inventory | $78.20M | $83.51M |
| Current assets | $231.47M | $230.69M |
| PP&E, net | $266.26M | $225.29M |
| Goodwill | $223.04M | $135.41M |
| Intangibles | $232.89M | $150.12M |
| Total assets | $986.29M | $770.05M |
| Current liabilities | $104.84M | $97.22M |
| Short-term debt | — | $9.91M |
| Long-term debt | $244.00M | $149.00M |
| Total debt | $244.00M | $158.91M |
| Total liabilities | $452.28M | $309.76M |
| Shareholders' equity | $534.01M | $460.29M |
| Net debt | $240.09M | $153.81M |
| Shares outstanding | 20.75M | 20.68M |
| Cash flow statement | ||
| Operating cash flow | $144.33M | $111.10M |
| Capital expenditure | $58.24M | $41.10M |
| Free cash flow | $86.09M | $70.00M |
| Investing cash flow | -$224.10M | -$127.95M |
| Financing cash flow | $78.58M | $14.81M |
| Depreciation & amortization | $52.54M | $39.95M |
| Stock-based compensation | $8.57M | $6.50M |
| Dividends paid | $15.66M | $14.63M |
Free plan shows the latest 2 periods; Pro shows all 17 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.